Ledermycin Capsules 150mg
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Ledermycin Capsules 150mg Demeclocycline Hydrochloride 150mg Capsules
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
LEDERMYCIN capsules each contain 150mg of demeclocycline hydrochloride.
3. PHARMACEUTICAL FORM
capsule, hard
4. CLINICAL PARTICULARS
4.1. Therapeutic Indications
For the treatment of infections caused by tetracycline-sensitive organisms. For example, LEDERMYCIN is highly effective in the treatment of infections caused by Borrelia recurrentis (relapsing fever), Calymmatobacterium granulinatis (granuloma inguinale), Chlamydia species (psittacosis, lymphogranuloma vereneum, trachoma, inclusion conjunctivitis), Francisella tularensis (tularaemia), Haemophilus ducreyi (chancroid), Leptospira (meningitis, jaundice), Mycoplasma pneumoniae (non-gonococcal urethritis), Pseumomonas mallei and pseudomallei (glanders and melioidosis), Rickettsiae (typhus fever, Q fever, rocky mountain spotted fever), Vibrio species (cholera). It is also highly effective, alone or in combination with streptomycin, in the treatment of infections due to Brucella species (brucellosis) and Yersinia pestis (bubonic plague). Severe acne vulgaris.
Other sensitive organisms include: Actinomyces israelii, Bacillus anthracis (pneumonia), Clostridium species (gas gangrene, tetanus), Entamoeba histolytica (dysentery), Neisseria gonorrhoeae and anaerobic species, Treponema pallidum and pertenue (syphilis and yaws).
For the treatment of chronic hyponatraemia associated with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) secondary to malignant disease, where water restriction is ineffective and the patient does not have concomitant cirrhosis.
4.2. Posology and Method of Administration
Oral administration.
For Antibiotic Use
Adults (capsules) - 600mg daily in 2 or 4 divided doses. For primary atypical pneumonia, the average daily dose is 900mg in 3 divided doses for 6 days.
Elderly - use with caution in elderly patients. (See Section 4.3 Contraindications and Section 4.4 Special warnings and special precautions for use)
Children - not recommended for children under 12 years of age.
For the treatment of Chronic Hyponatraemia due to SIADH
Adults only
Initially: 900mg-l200mg daily in divided doses
Maintenance dose: 600-900mg daily in divided doses
LEDERMYCIN should be swallowed whole with plenty of fluid while sitting or standing. Doses should be taken an hour before or 2 hours after meals as absorption of LEDERMYCIN is impaired by milk and food. Antibiotic therapy should be continued for one to three days after characteristic symptoms of fever have subsided. The incidence of rheumatic fever or glomerulonephritis following streptococcal infections suggests that therapy of a streptococcal infection should be continued for 8 full days even though symptoms have subsided.
LEDERMYCIN therapy in the treatment of chronic hyponatraemia due to SIADH should not be withdrawn without commencing other methods of control.
4.3 Contraindications
The use of LEDERMYCIN is contraindicated in patients with acute porphyria, patients who are pregnant or breast-feeding, children under 12 years of age, patients with a history of hypersensitivity to tetracyclines and patients with renal impairment.
4.4 Special warnings and precautions for use
LEDERMYCIN should be used with caution in patients with renal or hepatic dysfunction, or in conjunction with other potentially hepatotoxic or nephrotoxic drugs. Concurrent use with the anaesthetic methoxyflurane increases the risk of kidney failure. The anti-anabolic action of the tetracyclines may cause an increase in BUN. The treatment of chronic hyponatraemia may necessitate the administration of high doses of LEDERMYCIN for prolonged periods, so increasing the potential for nephrotoxicity (manifested by rises in plasma urea and creatinine) and photoallergic reactions. Cross-resistance between tetracyclines may develop in micro-organisms and cross sensitisation in patients. LEDERMYCIN should be discontinued if there are signs/symptoms of overgrowth of resistant organisms including candida, enteritis, glossitis, stomatitis, vaginitis, pruritis ani or staphylococcal enterocolitis.
Lower doses are indicated in cases of renal impairment to avoid excessive systemic accumulation and if therapy is prolonged, serum level determinations are advisable. Patients who have known liver disease should not receive more than 1g daily. In long term therapy, periodic laboratory evaluation of organ systems, including haematopoietic, renal and hepatic studies should be performed.
LEDERMYCIN has the greatest potential of the tetracycline analogues for causing photo-allergic reactions in hypersensitive persons. Such patients should be warned to avoid direct exposure to natural or artificial sunlight and to discontinue therapy at the first sign of skin discomfort. Exacerbation of pre-existing SLE has been reported with tetracyclines.
Patients taking oral contraceptives should be warned that if diarrhoea or breakthrough bleeding occur there is a possibility of contraceptive failure.
LEDERMYCIN may increase muscle weakness in patients with myasthenia gravis.
4.5 Interactions with other medicinal products and other forms of interaction
LEDERMYCIN should not be used with penicillins.
Tetracyclines depress plasma prothrombin activity and reduced doses of concomitant anti-coagulants such as Coumarins and phenindione may be required.
Absorption of LEDERMY CIN is impaired by the concomitant administration of milk and dairy products, food, iron, calcium, zinc, magnesium and particularly aluminium salts commonly used as antacids.
Absorption of tetracyclines is possibly reduced by kaolin, quinapril tablets (quinapril tablets contain magnesium carbonate), strontium ranelate, sucralfate, tripotassium dicitratobismuthate. The concomitant use of tetracyclines may reduce the efficacy of oral contraceptives; an increased incidence of breakthrough bleeding may also be experienced (See section 4.4 Special warnings and precautions for use).
There is a possible increased risk of benign intracranial hypertension with concomitant use of tetracyclines and retinoids, e.g. acitretin, isotretinoin, tretinoin. There is increased risk of ergotism when tetracyclines given with ergotamine and methysergide.
Typhoid Vaccine (oral): Antibacterials inactivate oral typhoid vaccine and therefore Ledermycin should be avoided for 3 days before and after oral typhoid vaccine.
4.6. Pregnancy and Lactation
LEDERMYCIN is contra-indicated during pregnancy and lactation.
Results of animal studies indicate that tetracyclines cross the placenta, are found in foetal tissues and can have toxic effects on the developing foetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy.
The use of tetracyclines during tooth development (last half of pregnancy and children to the age of 12 years) may cause permanent discoloration of the teeth (yellow-grey-brown). This adverse reaction is more common during long term use of the drugs but has been observed following repeated short term courses. Enamel hypoplasia has also been reported.
Tetracyclines have been found in the milk of lactating women who are taking a drug in this class. Permanent tooth discoloration may occur in the developing infant and enamel hypoplasia has been reported. Therefore, LEDERMYCIN should not be administered to lactating women.
4.7. Effects on Ability to Drive and Use Machines
Headache, dizziness, visual disturbances and rarely impaired hearing have been reported with tetracyclines and patients should be warned about the possible hazards of driving or operating machinery during treatment.
4.8 Undesirable effects
Gastrointestinal disturbances including nausea, vomiting, diarrhoea and rarely dysphagia have been reported. There have been a few cases of oesophagitis and oesphageal ulceration in patients taking oral tetracyclines in solid dose form, usually where medication was taken immediately before retiring or with inadequate fluids.
As with all antibiotics, overgrowth of resistant organisms may cause candidiasis, pseudomembranous colitis (Clostridium difficile overgrowth) glossitis, stomatitis, vaginitis, or staphylococal enterocolitis.
In common with other tetracyclines, transient increases in liver function test values, hepatitis, jaundice and hepatic failure have been reported rarely. A few cases of pancreatitis have been reported.
The most commonly reported dermatological reaction is photosensitivity. Erythematous, and maculo-papular rashes, pruritus, bullous dermatoses, exfoliative dermatitis and skin discolouration have occurred occasionally but serious skin reactions are rare.
Headache, dizziness, visual disturbances and rarely impaired hearing have been reported with tetracyclines. Bulging fontanelles in infants and benign intracranial hypertension in juveniles and adults have been reported. Treatment should cease if evidence of raised intracranial pressure, such as severe or persistant headache or blurred vision are noted. While the condition and related symptoms usually resolve soon after discontinuation of the tetracycline, the possibility of permanent sequelae exists. There have been isolated cases of myasthenia.
Hypersensitivity reactions including urticaria, Stevens-Johnson syndrome, angioneurotic oedema, anaphylaxis, anaphylactoid purpura, pericarditis and exacerbation of systemic lupus erythmatosus may occur.
Renal dysfunction, especially in patients with pre-existing renal impairment, and rarely, acute renal failure or nephritis, have been reported with tetracyclines.
Reversible nephrogenic diabetes insipidus can occur especially if treatment is prolonged and/or at high dosages.
Haemolytic anaemia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and eosinophilia have been reported rarely. When given over prolonged periods, tetracyclines have been reported to produce brown-black discoloration of the thyroid gland. No abnormalities of thyroid function are known to occur.
4.9. Overdose
No specific antidote. Gastric lavage plus oral administration of milk or antacids. Maintain fluid and electrolyte balance.
5. PHARMACOLOGICAL PROPERTIES
5.1. Pharmacodynamic Properties
Tetracyclines have a broad spectrum of anti-microbial activity and act by interfering with bacterial protein synthesis. They are active against a large number of gram positive and gram negative pathogenic bacteria, including some which are resistant to penicillin.
5.2 Pharmacokinetic properties
Tetracyclines are incompletely and irregularly absorbed from the gastrointestinal tract. Absorption is affected by the soluble salts of divalent and trivalent metals, milk and food.
Plasma concentrations of up to 2.4mg per ml have been reported 3 to 4 hours after an oral dose of 300mg, only falling to about 1mg per ml after 24 hours. 41-90% of circulating demeclocycline is bound to plasma proteins.
Tetracyclines are widely distributed throughout the body tissue and fluids, and are retained at sites of new bone formation and recent calcification. The biological half life of demeclocycline is 12 hours.
Tetracyclines are excreted in the urine and faeces.
5.3. Preclinical Safety Data
There are no other preclinical safety data of relevance to the prescriber apart from those already detailed in the SPC.
SUMMARY OF PRODUCT CHARACTERISTICS
6.1. List of Excipients
Powdered Cellulose, magnesium stearate, Colloidal Anhydrous Silica.
Capsule body and cap: titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (El72), erythrosine (El27), gelatin.
Printing on capsule: Shellac glaze, N-Butyl alcohol, Purified water, Propylene glycol (E1520), Dehydrated Ethanol, Ammonium Hydroxide (E527), Isopropyl Alcohol and black iron oxide (E172)
6.2. Incompatibilities
None.
6.3. Shelf Life
36 months
6.4 Special precautions for storage
Do not store above 25°C.
Blister pack-Store in original package in order to protect from light and moisture.
Container/Bottle - Keep the container/bottle tightly closed in the outer carton in order to protect from light and moisture
6.5 Nature and contents of container
Polypropylene containers - 20, 28 or 100 capsules.
Screw capped glass bottles - 100 capsules.
Blister pack - 20 capsules.
HDPE 0 45 mm round 50 ml plastic container containing 28 capsules
6.6. Instruction for Use/Handling
No special requirements.
7 MARKETING AUTHORISATION HOLDER
Mercury Pharmaceuticals Ltd Capital House,
85 King William Street,
London EC4N 7BL,
UK
8. MARKETING AUTHORISATION NUMBER
PL 12762/0154
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION 8 March 2004
10 DATE OF REVISION OF THE TEXT
02/03/2016